HighTower Advisors’s Travere Therapeutics TVTX Stock Holding History

HighTower Advisors’s Portfolio TVTX Stock Details TVTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-5,753	Closed	-$220K	–	3945
2025 Q4	$220K	Buy	+5,753	New	+$187K	﹤0.01%	3293

Other funds holding TVTX

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

NAMI

Nomura Asset Management International Philadelphia, Pennsylvania $58.4B AUM

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

HighTower Advisors's TVTX Position: Q1 2026 in Review

HighTower Advisors sold out of Travere Therapeutics (TVTX) in Q1 2026, closing a stake of 5,753 shares — an estimated $220K sold.

HighTower Advisors first reported a position in TVTX in Q4 2025 and held it in 1 quarter. The position peaked at $220K in Q4 2025. 260 funds tracked by Wall St. Rank hold TVTX as of Q1 2026.

HighTower Advisors reported no remaining Travere Therapeutics position as of Q1 2026 after selling out during the quarter.
HighTower Advisors sold 5,753 Travere Therapeutics shares in Q1 2026, an estimated $220K.
HighTower Advisors first reported a position in Travere Therapeutics in Q4 2025 and held it in 1 quarter.
HighTower Advisors's Travere Therapeutics position peaked at $220K in Q4 2025.
260 funds tracked by Wall St. Rank held Travere Therapeutics as of Q1 2026.

Based on HighTower Advisors's 13F filing for Q1 2026, filed 5 May 2026.